In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Complera (Gilead); Edurant (Centocor); Juluca (ViiV)
- INDICATIONS: HIV-1 infection
- CLASS: Antiretroviral, Non-nucleoside reverse transcriptase inhibitor
- HALF-LIFE: 50 hours
- FDA APPROVAL DATE: 06/10/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antacids, Atazanavir, Carbamazepine, Cimetidine, Clarithromycin, Darunavir, Delavirdine, Dexamethasone, Efavirenz, Erythromycin, Esomeprazole, Etravirine, Famotidine, Fluconazole, Fosamprenavir, Indinavir, Itraconazole, Ketoconazole, Lansoprazole, Lopinavir, Methadone, Nelfinavir, Nevirapine, Nizatidine, Ombitasvir/Paritaprevir/Ritonavir, Omeprazole, Oxcarbazepine, Pantoprazole, Phenobarbital, Phenytoin, Posaconazole, QT prolonging agents, Rabeprazole, Ranitidine, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Tipranavir, Troleandomycin, Voriconazole
- See adverse reactions attributed to class:
Complera is rilpivirine, emtricitabine and tenofovir; Juluca is rilpivirine and dolutegravir.
Please login to view the rest of this drug profile.
Page last updated 01/31/2024
